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PINK1The study of rare, inherited mutations underlying familial forms of Parkinson's disease has provided insight
into the molecular mechanisms of disease pathogenesis. Mutations in these genes have been functionally
linked to several key molecular pathways implicated in other neurodegenerative disorders, including
mitochondrial dysfunction, protein accumulation and the autophagic-lysosomal pathway. In particular, the
mitochondrial kinase PINK1 and the cytosolic E3 ubiquitin ligase parkin act in a common pathway to regulate
mitochondrial function. In this review we discuss the recent evidence suggesting that the PINK1/parkin
pathway also plays a critical role in the autophagic removal of damaged mitochondria–mitophagy. This
article is part of a Special Issue entitled Mitochondria: the deadly organelle.ondria: the deadly organelle.
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Parkinson's disease (PD) is the most prominent, progressive
movement disorder and the secondmost common neurodegenerative
disease affecting aging populations. The characteristic symptoms of
PD include postural instability, rigidity, resting tremor and bradyki-
nesia. A signiﬁcant proportion of individuals suffering from this
disorder appear to have no known genetic cause and are typically
referred to as sporadic or idiopathic patients. In contrast to this, 5–10%
of individuals with disease are classed as familial patients because
they have been shown to carry heritable, disease-associated muta-
tions in a series of genes referred to as the PARK genes [1]. To date, six
PARK genes have been identiﬁed which encode: α-synuclein (PARK1/
4), parkin (PARK2), PINK1 (PTEN-Induced Kinase 1—PARK6), DJ-1
(PARK7), LRRK2 (PARK8) and ATP13A2 (PARK9). Whilst both LRRK2
and PINK1 are protein kinases, the functions of the remaining genes
are diverse and in some cases, still partially unknown. However,
mutations in both LRRK2 and α-synuclein result in autosomal
dominant inherited disease whilst mutations in DJ-1, parkin, PINK1
and ATP13A2 all give rise to autosomal recessive disease.
Pathologically, PD is characterised by the degeneration of
dopaminergic neurons in the substantia nigra accompanied with the
presence and accumulation of proteinaceous aggregates, referred to as
Lewy Bodies (LB) or Lewy Neurites (LN), in the remaining neurons of
affected individuals [2]. Neuropathological analysis has conﬁrmedthat α-synuclein positive aggregates are a key component of LB and
LN in PD patients and these aggregates are frequently found in other
neurodegenerative disorders [2,3].
A common emerging theme in PD research has beenmitochondrial
dysfunction and its involvement with disease. Several lines of
evidence implicate mitochondria in PD including reduced complex I
activity in PD patients [4], reducedmitochondrial membrane potential
(ΔΨm) accompanied with increased ROS production in PD cell
models [5,6], alterations in mitochondrial ﬁssion–fusion events [7,8],
defects in mitochondrial trafﬁcking [9,10] and the striking observa-
tion that all of the PD related proteins are either mitochondrially
located or can associate with mitochondria [11–15]. Recently, a series
of studies involving the PD proteins parkin (an E3 ubiquitin ligase)
and PINK1 (a serine/threonine kinase with a mitochondrial targeting
sequence), mutations in which are the most common cause of
recessive PD [10,16] have highlighted a potential role for both
proteins in the clearance of mitochondria from cells via autophagy—
a process known as mitophagy [17]. This observation is intriguing
because defects in autophagy/mitophagy have been shown to
recapitulate a series of reported PD features namely: impaired
motor coordination, tremor and the accumulation of protein aggre-
gates/inclusion bodies in residual neurons [18,19]. In this article, we
review the process of mitophagy and its involvement in neurodegen-
eration with a particular emphasis on PD.
2. A brief word on autophagy
The autophagy-lysosome pathway (ALP) and the ubiquitin-
proteasome system (UPS) are the two most important mechanisms
that normally remove damaged proteins. Dysregulation of these
Table 1
Yeast ATG and mitophagy gene involvement in autophagy pathways and identiﬁed
human homologues.
Yeast gene Involved in macroautophagy
and/or Cvt?
Involved in
mitophagy?
Human homologue
ATG 1 √ √ ULK-1, ULK-2
ATG 2 √ √ ATG 2A, ATG 2B
ATG 3 √ √ ATG 3, ATG 3P
ATG 4 √ √ ATG 4A, ATG 4B,
ATG 4C, ATG 4D
ATG 5 √ √ ATG 5
ATG 6 √ √ Beclin1
ATG 7 √ √ ATG 7
ATG 8 √ √ LC3B
ATG 9 √ √ ATG 9A, ATG 9B
ATG 10 √ √ ATG 10
ATG 11 √ √ –
ATG 12 √ √ ATG 12, ATG 12P
ATG 13 √ √ –
ATG 14 √ √ ATG 14L
ATG 15 √ √ –
ATG 16 √ √ ATG 16L1, ATG 16L2
ATG 17 √ × –
ATG 18 √ √ –
ATG 19 √ × –
ATG 20 √ √ –
ATG 21 √ √ –
ATG 22 × × –
ATG 23 √ √ –
ATG 24 √ √ –
ATG 25 √ × –
ATG 26 × × –
ATG 27 √ √ –
ATG 28 √ × –
ATG 29 √ √ –
ATG 30 √ × –
ATG 31 √ √ –
ATG 32 × √ –
ATG 33 × √ –
UTH1 × √ –
YmeI × √ –
AUP1 × √ –
Mdm38 × √ –
Loss-of-function studies in yeast have identiﬁed 33 autophagy (ATG) genes and four
mitophagy speciﬁc genes. Many of the ATG genes perform multiple functions and
participate in more than one autophagy pathway. A tick indicates the involvement of
the gene whilst a cross shows that loss of this gene has no impact on the autophagy
pathway in question. The identiﬁed human homologues to these genes are listed.
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increasingly recognised as playing a pivotal role in the pathogenesis of
many neurodegenerative disorders [20].
Autophagy is the process by which unwanted, excess or damaged
cytosolic components are ‘self degraded’ by the cell through lysosomal
digestion. This catabolic process is a tightly regulated method of
maintaining the optimal balance of protein synthesis, degradation and
recycling of cellular resources. Autophagy plays a critical role during
embryonic and postnatal developmental processes with defects in
autophagy frequently displaying aberrant development of the central
nervous system (CNS) [21]. Autophagy additionally performs a
housekeeping role by eliminating damaged or dysfunctional proteins
and/or organelles and has also been implicated in the defence against
intracellular pathogen invasion [22–24]. Whilst autophagy is an
ongoing process, which does not require any stress or stimulus for its
induction, autophagy can also be induced by a number of conditions
including starvation/nutrient deprivation, reactive oxygen species
(ROS) production, oxidative stress and pharmacological insult
[17,25,26]. During nutrient starvation, autophagy facilitates the
breakdown of excess proteins or organelles to their component
parts and subsequently recycles them to meet the energy require-
ments of the cell. Three types of autophagy have been deﬁned:
macroautophagy, microautophagy and chaperone-mediated autop-
hagy (CMA) [24]. Macroautophagy and microautophagy can recycle
cellular components, including whole organelles, via non-selective
(housekeeping) or selective (speciﬁc targeted degradation) mechan-
isms [27]. When macroautophagy is employed, unwanted cytosolic
material is engulfed and delivered to the lysosome via a double
membrane bound vesicle called the autophagosome or autophagic
vacuole (AV) [27]. During microautophagy, however, cytosolic
components are taken up directly by the lysosome through invagi-
nation of the lysosome membrane. In contrast, CMA is a purely
selective form of autophagy and can only facilitate the removal of a
speciﬁc subset of cytosolic proteins containing the signature motif
KFERQ [28]. These proteins form a complex with chaperone proteins
e.g. Hsc70 in the cytoplasm and are directly transported across the
lysosomal membrane. Whilst all three mechanisms are important for
cellular function in mammals, dysregulation of macroautophagy has
been linked to a series of human diseases. These include numerous
forms of cancer and many forms of neurodegeneration [27]. Notably,
when no speciﬁc reference to the type of autophagy is given in the
text, authors refer to macroautophagy as autophagy.
3. Macroautophagy and mitophagy
The presence of mitochondria within autophagosome structures
was initially observed in mammalian cells by scanning electron
microscopy in 1957 [29]. Whilst the notion that mitochondria can be
degraded by autophagy is widely accepted, the fact that the process
can be selective has only recently come to light and the mechanisms
by which this occurs are not yet fully understood.
Over the past decade, our understanding of the molecular
mechanisms underlying and regulating macroautophagy has in-
creased dramatically. Studies using the yeast strain Saccharomyces
cerevisiae (S. cerevisiae) provided our ﬁrst insights into the process
and a series of mutation screens have identiﬁed 33 AuTophaGy (ATG)
genes to date [27,30]. The identiﬁcation of the ATG genes in yeast has
been instrumental in identifying mammalian ATG homologues
through sequence comparison [31]. In addition, these studies
highlighted differences between the autophagic processes and
machinery in yeast and mammals such as the existence of an
autophagy-like process, exclusively found in S. cerevisiae, called the
cytoplasm to vacuole targeting (Cvt) pathway (a biosynthetic process
which sequesters speciﬁc hydrolases into vesicles for subsequent
vacuole fusion) and the observation that only a few orthologues of the
yeast ATG genes are fully conserved in humans.The term “mitophagy”, coined by Lemasters in 2005 [17], is
deﬁned as “the speciﬁc and selective, targeted removal of excess or
damaged mitochondria from the cell via autophagy”. Since the
discovery of this process, mitophagy is thought to play a role in
maintaining a healthy mitochondrial population via removal of
dysfunctional/depolarised mitochondria and/or mitochondria pro-
ducing the highest levels of damaging ROS [32]. In the following
section, we summarise what is currently known about mitophagy in
yeast and humans and introduce the reader to some of the methods
used to study the process.3.1. Mitophagy in yeast
Studies in S. cerevisiae provided the ﬁrst genetic evidence that
mitochondrial degradation by autophagy could be a selective process
[33]. A number of the ATG genes have been reported to play a role in
mitophagy in yeast however, these genes are not exclusively involved in
mitophagywithmanyplaying additionally roles in themacroautophagy
process in general and/or in the Cvt pathway (listed in Table 1). To date,
however, loss-of-function screens in yeast have identiﬁed ﬁve genes
involved in mitophagy: UTH1, YmeI, AUP1, mdm38/Mkh1 and ATG32.
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ordination with ATG proteins, signals for mitochondria to be selectively
removed [34]. In addition, loss of UTH1 function eliminated selective
mitophagy indicating that the protein is critically involved in the process
[33]. YmeI encodes a putative ATPase which, when deleted, induces
mitophagy [35]. However, additional studies are required to determine
whether mitophagy is initiated as a direct consequence of YME1 protein
loss or whether compensation mechanisms inadvertently induce the
process. Notably, both UTH1 and YmeI are also reported to play a role in
mitochondrial biogenesis but it is currently unclear how these proteins
function in this process [36,37]. AUP1 (Ancient ubiquitous protein 1)
encodes a mitochondrial phosphatase, which was shown to be essential
for mitochondrial elimination in non-dividing cells during so called
efﬁcient stationary phase mitophagy [38]. AUP1 regulates mitophagy by
altering the phosphorylation status of the retrograde signalling pathway
(RTG) transcription factor RTG3 [39]. The RTG is a signalling pathway
responsible for monitoring mitochondrial function and for inducing
nuclear responses during times of mitochondrial stress. Mdm38/Mkh1, a
mitochondrial inner membrane protein, is an essential component of the
K+/H+ exchange system. In the absence of mdm38, mitochondria
become swollen, lose their ΔΨm and fragment before being removed
from the cells via microautophagy. Strikingly, treatment of mdm38
deﬁcient cells with an inhibitor of the K+/H+ exchanger prevents this
form of mitophagy indicating that in yeast, the K+/H+ exchanger may
play an important role in mitochondrial turnover. The most recent yeast
mitophagy speciﬁc protein to be identiﬁed is ATG32 [40,41]. ATG32
localises to mitochondria and is described as a mitochondrially anchored
receptor. Upon induction of mitophagy, ATG32 binds to ATG11, an
adapter protein known to be required for selective autophagy. ATG32 has
therefore been proposed to function as a mitophagy speciﬁc receptor,
which regulates the selective removal of mitochondria [41].Fig. 1. A simpliﬁed schematic of macroautophagy in mammals. (a) Activation of autophagy v
regulated by the ULK1/2–ATG complex and the PI3kinase complex which includes Beclin1an
LC3-I is cleaved by ATG4 to produce lipidated LC3-II. (d) LC3-II is recruited to the autophago
content digestion.3.2. Mitophagy in humans
Subsequent studies in mammalian systems have revealed a series
of homologues of the yeast ATG genes and subsequent molecular
studies have reported over 150 additional genes involved in human
autophagy. A list of these genes and relevant publications can be
accessed via the HADb—Human Autophagy Database (http://www.
autophagy.lu/index.test.html). However, to date no homologues of
the mitophagy speciﬁc genes in yeast (described in 3.1.) have been
identiﬁed and, through loss of function studies, only two proteins
have been reported to directly affect mitochondrial autophagy in
mammalian cells: BniP3 (Bcl-2 and adenovirus E1B 19 kDa-interact-
ing protein 3) and NIX/Bnip3L (Bnip3-like protein X).
BNIP3 and NIX are both pro-apoptotic members of the Bcl-2 family
of proteins. They each contain a BH3 only domain and amitochondrial
targeting sequence, which localises them to mitochondria [42] (and
this issue of BBA). BNIP3 has been linked to hypoxia-induced
mitophagy in cardiomyocytes. In these studies, increased Bnip3
expression correlated directly with a decrease in mitochondrial DNA
copy number which was accredited to mitochondrial removal via
autophagy [43]. In addition, Bnip3 interacts with the anti-apoptotic
protein Bcl-2. Interaction of Bnip3 with Bcl-2 abrogates the ability of
Bcl-2 to remain bound to the autophagy protein Beclin-1 (ATG6),
which promotes autophagy once released [44] (Fig. 1). In contrast,
examination of NIX deﬁcient mice revealed that loss of NIX function
impairs normal reticulocyte development through defects in mito-
chondrial clearance and mitochondria predominantly associate with
outer autophagosomal membranes [45]. This observation led to the
hypothesis that NIX is required for mitochondrial incorporation into
autophagosomes during reticulocyte development and that a lack of
mitophagy is deleterious to cells. Importantly, subsequent work hasia ULK1/2 is induced by inhibition of the TOR pathway. (b) Autophagosome formation is
d Vps34. (c) During elongation and closure of the autophagosome membrane, cytosolic
some membrane. (e) The complete autophagosome fuses with the lysosome to enable
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like proteins LC3 and GABARAP, which are required for autophago-
some formation [46,47]. The interaction between NIX and LC3 is
strengthened under conditions of mitochondrial stress or in the
presence of pharmacological agents which block autophagy, whilst
GABARAPwas shown to be recruited to depolarised mitochondria in a
NIX dependent manner (Fig. 2) [47]. Novak et al. therefore conclude
that NIX is a selective autophagy receptor, which mediates the
removal of damaged mitochondria. NIX expression, which can be
induced by cell stress, growth or differentiation, promotes outer
mitochondrial membrane permeabilisation and allows the release of
cytochrome c to induce apoptosis. Importantly, normal reticulocyte
development could be restored in NIX deﬁcient cells by treatment
with pharmacological agents, which depolarise mitochondria. This
observation therefore suggests that NIX may initiate mitophagy via
mitochondrial depolarisation. Notably, NIX expression was upregu-
lated in a PD model system where neuronal PC12 cells were exposed
to 6-hydroxydopamine (a neurotoxin which speciﬁcally kills dopa-
minergic and noradrenergic neurons) [48]. In this system, however,
NIX interacts with POSH (plenty of SH3 domains), which is known to
play a role in activation of the JNK/c-Jun apoptotic pathway, and
drives neuronal death via c-Jun activation. In addition, expression of aFig. 2. PINK1 and parkin in mitophagy—proposed model. Upon mitochondrial membrane de
NIX translocates to themitochondria. NIX and full-length PINK1 recruit parkin to themitocho
recruits p62 while NIX recruits GABARAP to the mitochondria. NIX binds LC3, which additidominant negative NIX mutant, which can no longer target to
mitochondria, protects against neuronal death in this system. These
results suggest that loss of NIX function could be protective in neurons
subjected to stress. However, whether dysregulated mitophagy plays
a role in neuronal death has yet to be investigated in this system.
Recently, NIX was also reported to play a role in the translocation of
the PD associated protein parkin to mitochondria (see Section 6.1 and
Fig. 2) and for induction of autophagy via ROS stimulation [49].
Through a series of recent studies, parkin may represent a new
mitophagy speciﬁc protein in mammals (addressed in Section 6.1).3.3. Assessing mitophagy in mammalian systems
Studies investigating mitochondrial turnover/degradation by
autophagy have typically been performed in cell types/tissues that
naturally eliminate mitochondria during their maturation or devel-
opment e.g. lens, erythrocytes and sperm [37]. In cell types where this
does not occur, cell stressors have been utilised to induce autophagy
and mitochondrial turnover is subsequently assessed. The most
common method to induce autophagy is through inhibition of the
target of rapamycin (TOR) kinase pathway. Inhibition of TOR viapolarisation, full-length PINK1 accumulates at the outer mitochondrial membrane and
ndria, which leads to parkin-dependent ubiquitination of VDAC. Ubiquitination of VDAC
onally binds p62 and depolarised mitochondria are removed via autophagy.
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ULK1 kinase and induces autophagosome production (Fig. 1) [50].
Initial studies by Lemasters et al. implicated opening of the
mitochondrial permeability transition pore (PTP) to mitochondrial
autophagy [51,52]. However, subsequent conﬂicting reports have
emerged and at present there is still debate over the involvement of
PTP in mitophagy initiation [53]. A common mitochondrial feature,
which appears to accompanymitophagy in human cells, is a reduction
or loss of ΔΨm. Therefore, pharmacological treatments, which induce
mitochondrial membrane depolarisation e.g. uncoupling reagents
such as FCCP and CCCP, are also frequently used to assess mitophagy.
In addition, mitophagy can also be induced by photo damage, ROS
(e.g. H2O2) production, the MEK/ERK kinase signalling pathway and
increased or induced mitochondrial ﬁssion [32,53,54]. Irrespective of
the stimulus, the assays used to assess mitophagy frequently utilise
markers of autophagosomes tomonitor the process. Autophagy can be
assessed by electron microscopy, immunoﬂuorescence and biochem-
ical approaches. A comprehensive description of these methods, along
with their pros and cons was published a few years ago and we would
subsequently recommend it to interested parties [55]. However, for
the purpose of this review, we brieﬂy introduce two of the methods
used to assess mitophagy in recent PD studies below.
Microtubule-associated protein light chain 3 (MAP-LC3, LC3) is the
mammalian homologue of ATG8. Three forms of LC3 exist: the full-
length newly synthesised protein (LC3), a soluble form generated by
cleavage at the C-terminus by ATG4B (LC3-I) and a lipidation form
(LC3-II) [25,56]. LC3-I, which resides in the cytoplasm, is converted to
LC3-II through two-ubiquitin like modiﬁcations, which covalently link
the protein to phosphatidylethanolamine (PE) [24]. Importantly, LC3-
II then localises to autophagosomal membranes and thus the levels of
LC3-II in a cell are frequently used to demonstrate induction of
autophagy [57]. Fluorescently labelled LC-3II (GFP-LC3-II) is one of the
most common methods for assessing autophagy via microscopy and
live imaging experiments. In addition, the presence of ﬂuorescent
mitochondrial markers (e.g. mitotracker, DsRed-mito) within a GFP-
LC3-II labelled autophagosome is frequently used to demonstrate
mitophagy in mammalian systems [58].
Sequestosome 1 (P62/SQSTM-1) is a multi-functional adaptor
protein, which interacts with ubiquitinated proteins and is thought to
be involved in the delivery of ubiquitinated proteins/protein
aggregates to both the ubiquitin proteosome system (UPS) or
autophagosome for degradation [59]. P62 interacts with LC3-II,
becomes incorporated into the autophagosome and subsequently
degraded [60]. Impaired autophagic activity leads to an accumulation
of p62 in cells [55]. Consequently, the levels of p62, assessed by
Western blot or immunoﬂuorescence, are frequently used as a marker
for impaired/defective autophagy. Through studies in neurodegener-
ative models, P62 is thought to function in autophagy as a selective
means to sequester ubiquitinated protein aggregates into autophago-
somes and has been shown to accumulate in the LB/LN of PD patient
neurons [61,62].
4. Autophagy and mitophagy in neurons
To date, the majority of investigations to unravel the mechanisms
underlying mitophagy, and hopefully elucidate its role in disease
pathogenesis, have been performed in mitotic cells. These studies
have been instrumental in demonstrating that autophagy and
mitophagy are differentially regulated in different tissues/cell types
and therefore the study of these processes in post-mitotic long-lived
cells such as neurons is critical. Assessment of autophagy in the CNS,
using ATG5 and ATG7 knockout mice, revealed that an autophagic
deﬁcit results in neuronal degeneration and the accumulation of
ubiquitin labelled intracytoplasmic inclusion bodies in remaining
neurons [18,19]. These studies demonstrate the critical role autop-
hagy plays in maintaining neuronal health (for a detailed review see[60]) but also highlight the fact that not all neurons show the same
level of susceptibility to impaired autophagy. There are three potential
explanations for the differential susceptibility of neuronal popula-
tions. One is that different types of neurons employ different
compensatory mechanisms in response to impaired autophagy.
Alternatively the local environment of the neurons could affect how
the neurons respond to stress or toxic insult. However, the observed
differences could also indicate that different types of neurons have
differential rates of basal autophagy and therefore neurons which are
subjected to higher levels of stress and subsequently require higher
levels of autophagy, are more at risk of damage/death over time.
Critically, autophagy is known to decrease with age [63]. Therefore, if
the latter explanation is true, this could additionally explain why
subsets of neurons are also at risk of irreparable damage/death during
the human lifespan. Investigations to identify the reason behind
selective neuronal degeneration in the ATG knockout mouse models
could provide a great deal of insight into the selective loss of neuronal
populations in human disease e.g. dopaminergic neurons in PD.
However, one interesting study inmice showed that male neurons are
more susceptible to autophagic death than female neurons [64],
which implies that gender speciﬁc differences could also play a role in
differential regulation of autophagic processes. As PD predominantly
affects male members of the population, it would be interesting to
assess if the observations inmice are recapitulated in humans. If this is
the case then studies using healthy mouse neurons could potentially
aid our understanding of the gender speciﬁc susceptibilities and aid in
the development of therapeutics.
Notably, autophagosomes are rarely observed in healthy neurons.
At present, the reasons behind this are unknown but several
hypotheses have been put forward to explain this observation. In
the ﬁrst scenario it is assumed that a lack of autophagosomes indicates
that neurons have high basal autophagic rates compared to other cell
types and autophagic material is rapidly cleared from the cell [60].
However, the absence of autophagosomal structures could also
indicate that neurons utilise an alternative, as yet unidentiﬁed,
autophagic pathway. Studies have shown that, in neurons, a
starvation stimulus does not induce LC3-II labelled autophagosomes
and under normal conditions LC3 exists predominantly in its soluble
LC3-I form [65]. LC3-I is known to bind to microtubule associated
protein 1B (MAP1B), a protein expressed at high levels in neuronal
cells. The production of LC3 positive autophagosomes can be reduced
through MAP1B expression and hence the enriched MAP1B environ-
ment of neuronsmay also explain the lack autophagosomes [65,66]. In
addition, a key regulator of autophagy in neurons is insulin [66]. Loss
of insulin signalling directly impacts on the TOR pathway and results
in neuronal autophagy. The lack of autophagosome formation upon a
starvation stimulus is thought to be due to compensatorymechanisms
of nutrient supply from surrounding astrocytes and peripheral organs.
At present, little is known about the regulation or dysfunction of
mitophagy in neurons. Given their high dependence on mitochondria
however, one would assume that an inability to remove dysfunction-
al/damaged mitochondria from the cell would have severe and
detrimental consequences over time. In several models of PD,
enlarged or swollen mitochondria have been reported [7,8,67–69].
This observation potentially highlights a signiﬁcant role for mito-
phagy in PD pathogenesis. In addition, a study by Liang et al. reported
that in healthy mice, substantia nigra DA neurons have a reduced
mitochondrial mass compared to other neurons in the substantia
nigra [70]. We are not aware of alterations in mitochondrial mass in
human DA neurons, but if these neurons do have smaller mitochon-
drial populations, it may explain why these cells are particularly
sensitive to mitochondrial dysfunction. A comparative analysis of
mitochondrial mass in DA neurons, and additional neurons degraded
in PD would therefore be of interest. However, key studies
investigating mitophagy in neurons under healthy physiological
conditions are lacking and as a result, it is unclear where the problem
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mitophagy and mitochondrial biogenesis must be maintained to meet
the energy requirements of the cell. Failure to maintain an optimal
healthy mitochondrial population, through defects in either mito-
phagy or biogenesis could explain why speciﬁc tissues like the brain,
which critically depend on mitochondrial function, are most vulner-
able to dysfunction in aging organisms.
5. Autophagy and neurodegenerative diseases
Protein aggregation, mitochondrial impairment and oxidative
stress are common to a number of neurodegenerative diseases.
Speciﬁcally protein aggregation presents one of the common features
in numerous neurodegenerative disorders including the α-synuclein
containing LB/LN in PD, the beta-amyloid plaques in Alzheimer's
disease (AD) and the mutant huntingtin cytoplasmic inclusions in
Huntington disease (HD).
Defective autophagy was initially implicated in neurodegenerative
disease because increased levels of autophagic vacuoleswere observed
in AD, HD and PD patient brain tissues as well as in animal models of
each disease (reviewed in [71]). Moreover it has been shown that
knockdown of ATG genes resulted in neurodegeneration and the
presence of cytoplasmic inclusions (discussed in Section 4) [18,19].
Bothα-synuclein [72–74] and superoxide dismutase (mutations in
the SOD1 gene encoding superoxide dismutase are associated with
familial amyotrophic lateral sclerosis or ALS) [75] are eliminated by
autophagy. In addition, the PD related kinase LRRK2 has recently been
shown to regulate autophagy and localise to autophagic vacuoles
[76,77]. Alegre-Abarrategui et al. have demonstrated that loss of
LRRK2 resulted in an increase in autophagic activity in human cells
(Fig. 1). Importantly, expression of LRRK2 carrying either the G2019S
or R1441C PD related mutation, resulted in a signiﬁcant accumulation
of autophagic vacuoles within cells [77]. Dysregulation of the ALP was
also reported in the knockout LRRK2mousemodel where a signiﬁcant
amount of aggregated α-synuclein and ubiquitinated proteins
accumulated in the kidneys of these animals in an age-dependent
manner [76]. In contrast to the ﬁndings of Alegre-Abarrategui et al.,
however, these autophagy-lysosomal defects were not observed in
the R1441C knock in mouse model and hence the impact of LRRK2 PD
related mutations on ALP requires further investigation [76]. As
mentioned previously, TOR is a pivotal player in autophagy [78] and
notably induction of TOR-dependant autophagy via rapamycin leads
to a decrease of mutant huntingtin aggregates and prevents
neurodegeneration in a mouse model of HD [79]. Furthermore
trehalose, a TOR-independent autophagy enhancer was shown to
accelerate the clearance of mutant huntingtin and α-synuclein [80].
The authors have further shown that trehalose and rapamycin
together exert an additive effect on the degradation of these
aggregate-prone proteins due to increased autophagic activity [80].
If defective autophagy plays a crucial role in neurodegeneration in
general, its implication in PD in particular is increasingly recognised.
Evidence for this comes from recent studies showing that adminis-
tration of L-DOPA, a precursor to the neurotransmitter dopamine
clinically used to treat PD patients, in a mouse model of parkinsonism
led to dopamine D1 receptor-mediated activation of the TOR pathway
[81]. In addition, inhibition of TOR activation via rapamycin treatment,
protected against neuronal death in toxin cell and animal models of
PD [82,83]. Two subsequent studies in Drosophila have strengthened
the link between PD-associated proteins and TOR-dependent signal-
ling. Effectively Imai et al. have reported 4E-BP, a member of the TOR
pathway, as a potential substrate of LRRK2 in Drosophila [84].
However whether 4E-BP is a direct authentic substrate of LRRK2
remains unclear [85]. Further experiments in Drosophila showed that
4E-BP over-expression could rescue PINK1 and parkin knockout
phenotypes [86]. All together these studies suggest a link between
some of the PD-associated genes and the TOR pathway in Drosophila.Further studies will be required to conﬁrm this possible functional
interaction between PD-associated genes and TOR in mammals.
Finally TOR-dependant signalling has also been implicated in other
neurodegenerative diseases such as AD and ALS [87,88].
The lysosomal system is essential for completion of autophagy-
initiated protein and organelle degradation and there is increasing
evidence that lysosomal dysfunction is another important process in a
variety of neurodegenerative diseases, including AD, PD, HD, and ALS
[89]. One of the examples for neurodegeneration caused by deﬁciency
of enzymes in lysosomes is lysosome storage disorder, which is an
inherited metabolic disease, characterised by accumulation of various
toxic materials in neurons as a result of the lysosomal enzyme
deﬁciencies [90,91]. It has been shown that wild-type α-synuclein,
but not the mutant α-synuclein, is selectively translocated into
lysosomes for degradation by the CMA pathway [92]. Moreover
Xilouri et al. have shown that expression of mutant α-synuclein and
in some cases wild-type α-synuclein induced CMA dysfunction,
therefore mediating lysosomal dysfunction and eventually leading
to neuronal death [93]. It has also been shown that lysosomal
dysfunction accompanies α-synuclein aggregation in a progressive
toxic mousemodel of PD [94], and that mutations in ATP13A2, another
PD-associated gene encoding a lysosomal ATPase, lead to defective
autophagy and aggregation of α-synuclein in PD [95,96]. Ultrastruc-
tural studies of PINK1-deﬁcient cells often display an increased
lysosomal content [97–99]. Finally mutations in the gene encoding
glucocerebrosidase (GBA), the enzyme deﬁcient in the lysosomal
storage disorder Gaucher disease have recently been shown to be
associated with the development of PD [100]. All together these
observations support the hypothesis that lysosomal malfunction is
another important cause of neurodegenerative diseases, in particular
PD.
In summary the fact that decreased autophagic activity (as
demonstrated by accumulated autophagosomes) was found in
degenerating neurons of human brains suffering from AD, PD and
HD supports the concept that autophagy may act as a protective
aggregate clearance pathway. Thus as a result of defective autophagy,
protein plaques and aggregates would accumulate in neurons,
resulting in neurodegeneration (reviewed in [101]).
6. Mitophagy and neurodegenerative diseases
Aside from the degradation of cytosolic aggregates, the autophagic
pathway is also involved in the turnover of entire organelles such as
mitochondria. Mitophagy is, to date, the only identiﬁedmechanism by
which mitochondria are recycled. Alterations in mitochondrial
function and dynamics as well as in the mitophagic pathway are
increasingly recognised as being implicated in a number of neurode-
generative diseases [102–104]. For example mitochondria have been
shown to be key targets of increased autophagic degradation in AD
and PD [105]. In the following section we focus on recent discoveries
highlighting the emergent role of mitophagy in PD pathogenesis.
6.1. Mitophagy and Parkinson's disease—PINK1 and Parkin
Asmentioned in Section 3.2, the precisemolecularmechanisms for
mitochondrial recognition by autophagy are just beginning to be
elucidated. However, Chu et al. have shown that when autophagy was
induced by the parkinsonian neurotoxin MPP+, mitochondrial
degradation could be inhibited by knockdown of ATG genes.
Furthermore this study implicated that mitophagy occurred indepen-
dently of the PI3K/Beclin1 pathway but was dependant upon MAPK/
ERK signalling instead [106]. The PI3K/Beclin1 kinase complex is
known to be involved in regulating autophagosome formation in
mammals (Fig. 1). Beclin1 is known to interact with full length PINK1
which drives autophagy inmammalian cells, however, whether PINK1
is involved with the PI3K/Beclin1 complex is currently unknown
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autophagy was also observed in neurite retraction elicited by the
G2019S PDmutant of LRRK2 [108]. Interestingly Zhu et al. had already
shown that phosphorylated ERK was localised to mitochondria and
autophagosomes in Lewy body diseases [109]. Dagda et al. have
further shown that mitochondrial localisation of active ERK2 was
necessary to increase toxin-induced mitophagy in the dopaminergic-
like neuronal cell line SH-SY5Y [54]. Whether ERK promotes diffuse or
mitochondria-selective autophagy remains unclear and understand-
ing the mechanisms by which ERK promotes mitophagy as well as
identifying mitochondrial speciﬁc targets of ERK may offer avenues
for future research in PD.
The most recent candidate for ATG5-dependant mitophagy in
mammals is parkin [110], which may clear damaged mitochondria by
recruiting proteins such as ubiquitin and p62 [111]. Through a series
of high-resolution imaging experiments, Narendra et al. ﬁrst demon-
strated that, although the E3 ubiquitin ligase parkin was primarily
cytosolic, it was selectively recruited to damaged or depolarised
mitochondria in mammalian cells. Moreover the authors demonstrat-
ed that after recruitment, parkin was responsible for mediating the
uptake of mitochondria by autophagosomes and their subsequent
degradation [110,112]. In this study, parkin recruitment to the
mitochondria was shown to be voltage-dependent and independent
of ATP levels or pH. All together these ﬁndings suggest that parkin-
dependant elimination of dysfunctional mitochondria with a de-
creased mitochondrial membrane potential may be implicated in the
pathogenesis of PD [113].
Although prior studies suggest that PINK1 and parkin interact
genetically to regulate mitochondrial function [7,114–116], the
molecular pathway/s used by PINK1 and parkin to regulatemitophagy
remained unknown. A number of recent studies have however
provided some molecular clues on how PINK1 may regulate parkin-
mediated mitophagy and how PD-associated PINK1 and parkin
mutations result in defective mitophagy. Dagda et al. have shown
that stable knockdown of PINK1 in SH-SY5Y cells induced mitophagy
through effects on oxidative stress and mitochondrial ﬁssion whereas
overexpression of PINK1 stabilised mitochondrial networks. They
have also shown that parkin further enhanced this protective
mitophagic response, suggesting that PINK1 and Parkin may cooper-
ate to maintain mitochondrial homeostasis [117]. Interestingly, PINK1
and parkin have the opposite effect in Drosophila (with loss of
function inducing mitochondrial fusion and overexpression driving
ﬁssion) reviewed in [10]. Whilst the roles of PINK1 and parkin in
mitophagy have not yet been described in Drosophila, future studies to
investigate their role/s in the process should prove exceptionally
interesting to the ﬁeld. Vives-Bauza et al. demonstrated that the
relocation of parkin to mitochondria was dependent on PINK1
expression and that mutations in either PINK1 or parkin impaired
mitochondrial trafﬁcking, especially in the perinuclear region, a sub-
cellular area where defective mitochondria could be targeted for
autophagy [118]. Furthermore Lin and Kang have demonstrated that
PINK1 cleavage was inhibited in damaged mitochondria that had a
decreased mitochondrial membrane potential [119]. Narendra et al.
have further shown that full length PINK1 accumulates on these
dysfunctional mitochondria, leading to the recruitment of parkin at
the outer membrane of these damaged mitochondria and eventually
their degradation bymitophagy (Fig. 2) [120]. Similarly, a reduction in
mitochondrial membrane potential was reported to stabilise PINK1
mitochondrial accumulation. As a result parkin is recruited from the
cytosol to the depolarised mitochondria where it becomes active and
can initiate mitophagy. Notably, PINK1-dependent mitochondrial
localisation has been shown to be necessary to liberate the latent
ubiquitin ligase activity of parkin [121]. These combined studies
would therefore suggest that accumulation of full-length PINK1 at the
mitochondria is required to recruit parkin to the organelle. Geisler et
al. have further shown that PINK1 kinase activity and its mitochon-drial targeting sequence were necessary to induce translocation of
parkin to depolarised mitochondria, which further requires parkin E3
ubiquitin ligase activity. In addition they have shown that the
mitochondrial voltage-gating channel VDAC (voltage-dependent
anion channel 1) was a target for parkin-mediated Lys27 poly-
ubiquitination and p62-mediated autophagy (Fig. 2) [111]. However,
a recent conﬂicting study in primary dermal ﬁbroblasts originating
from PD patients demonstrated that mitochondrial accumulation of
full length PINK1, whilst sufﬁcient, was not necessary for the stress-
induced mitochondrial translocation of parkin. Furthermore the
authors showed that parkin mitochondrial translocation was inde-
pendent of the mitochondrial membrane potential [122]. More
recently, NIX, a protein already implicated in mitophagy (see
Section 3.2) was reported to be critical for parkin translocation to
the mitochondria (Fig. 2). Notably, the C-terminus of NIX, which is
required for localisation of NIX to mitochondria, is required for parkin
translocation [49]. In addition, a role for parkin in the selective
removal of mitochondria harbouring mtDNA mutations has recently
been reported [123]. In this study, parkin overexpression was shown
to eliminate mitochondria with deleterious mtDNA mutations
thereby ensuring the maintenance of a healthy mitochondrial
population. Notably, patients heterozygous for PINK1 have been
reported to harbour mtDNA mutations [124]. If PINK1 is involved in
parkin translocation to mitochondria, then the deﬁcit in PINK1 in
these patients may explain the retention of deleterious mtDNA
mutations in PINK1 PD patients.
However, the conﬂicting views, regarding the mechanism regu-
lating parkin translocation to mitochondria, highlight the need for
more experiments to be performed where protein function can be
assessed at the endogenous level and in a neuronal setting.
Unfortunately with regards to PINK1, the scientiﬁc community has
so far been limited by the difﬁculty of detecting the endogenous
protein. This is due to the absence of an antibody capable of detecting
PINK1 in a speciﬁc and reproducible manner but additional problems
are incurred due to the short half-life of PINK1 and its cleavage
products (approx 30 min) [119]. Full length PINK1, but not its cleaved
forms have recently been shown to enhance autophagy through its
interaction with Beclin1, a key pro-autophagic protein already
implicated in the pathogenesis of AD and HD [107]. Although
strengthening the link between PINK1 and autophagy, it is difﬁcult
to correlate these ﬁndings with the study of Chu et al., which shows
that MPP+ induced autophagy is Beclin1 independent [106]. This
discrepancy simply highlights the fact that the macroautophagy
process, observed in PD, is probably far more complex than previously
thought, with various autophagy pathways being implicated in the
process.
Importantly the study performed by Geisler et al. provides a
missing link between ubiquitin and the two degradation systems, UPS
and ALP [111]. In Drosophila cells ubiquitination of the profusion
factor mitofusin may provide another mechanism by which damaged
mitochondria are targeted for degradation by PINK1/parkin-depen-
dent autophagy [125]. Together, these studies suggest that mutations
in either parkin or PINK1 may alter mitochondrial turnover, which in
turn, may cause the accumulation of defective mitochondria and,
ultimately, neurodegeneration in PD (for comprehensive reviews,
[101,126–128]. Although these studies represent amajor step forward
towards deﬁning the cellular function of the PINK1/parkin pathway in
removal of dysfunctional mitochondrial by mitophagy, many issues
remain to be clariﬁed.
7. Future perspectives—mitophagy and PD
Over the past few years, the involvement of PD associated genes
with autophagy and mitophagy has come to light. Whilst the roles
that these proteins play are beginning to be understood, a series of
questions remain to be addressed. Predominantly, the mechanisms
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remain unclear. Effectively, since parkin does not have a predicted
mitochondrial targeting sequence (MTS), the current studies impli-
cate PINK1, NIX or environmental stress as possible drivers of parkin
to the outer mitochondrial membrane (omm). Subsequent investiga-
tions to reveal whether endogenous PINK1 and/or NIX interact with
parkin on their way to the mitochondria or exclusively at the
mitochondria and whether parkin can still translocate to mitochon-
dria in NIX deﬁcient neurons would help to clarify the situation.
Notably, PINK1 was reported to phosphorylate parkin on Thr175,
which promoted parkin localisation to mitochondria [14]. In this
study, parkin phosphorylation by PINK1 was assessed in vitro and at
present these data have not been reproduced in vivo. Given the recent
ﬁndings that NIX has been shown to be essential for parkin
mitochondrial translocation, it would be interesting to assess whether
the interaction between parkin and NIX is dependent on parkin's
phosphorylation status or whether NIX perhaps functions as an
adaptor to aid parkin phosphorylation. PINK1 kinase activity has been
shown to regulate the function of several mitochondrial proteins, such
as the TRAP1 chaperone protein and the Omi/HtrA2 protease
[129,130]. It has therefore been proposed that PINK1, HtrA2 and
parkin interact to maintain mitochondrial homeostasis [117]. Inter-
estingly, a recent study showed that Omi/HtrA2 could promote
autophagy, therefore facilitating the degradation of mutant α-
synuclein and truncated huntingtin, proteins associated with PD and
HD respectively [131].
One inconsistency raised by the studies on PINK1 and parkin is the
observation that damaged mitochondria can stabilise full length
PINK1 in the outer mitochondrial membrane. Lin and Kang reported
that the integrity of the mitochondrial membrane was crucial for
PINK1 cleavage and, under depolarising conditions, full-length PINK1
accumulated on the outer mitochondrial membrane [119]. Whilst the
results of Narendra et al. support these ﬁndings, the study by Vives-
Bauza et al. showed that the levels of both full-length and cleaved
PINK1 increased upon mitochondrial depolarisation [118]. Further
studies to assess the proteolysis and proteosome-dependent clear-
ance of PINK1 under normal and mitochondrial-depolarising condi-
tions will therefore be required to clarify the issue.
The additional queries of whether mitochondria necessarily need
to be depolarised in order to be targeted for PINK1/parkin-dependent
mitophagy is a prominent area where additional investigations are
needed. Notably in the absence of mitochondrial membrane depolar-
isation, several manipulations that increase the levels of PINK1 at the
omm are sufﬁcient to recruit Parkin to mitochondria and promote
mitophagy [120]. Other PD-associated proteins, such as DJ-1, LRRK2
and α-synuclein have been reported to be at least partially located to
the mitochondria and to interact with PINK1 and/or parkin in
mammalian cells [99,132–135]. Whether these proteins interact
with the PINK1/parkin mitophagy pathway remains to be clariﬁed.
At present, the major limitation of most of the studies on PINK1/
parkin-dependent mitophagy is the reliance on overexpression of
parkin or PINK1 in mitotic cells. To clarify many of the issues raised
above there is an indispensable need to re-evaluate the selective
mitophagy pathway in post-mitotic neurons expressing the endoge-
nous wildtype or mutant parkin and PINK1 proteins. The use of iPS-
differentiated neurons from normal individuals and patients with
mutations in the PD-associated genes is a very promising tool and the
production of knock-in mouse or rat models for these PD genes would
be indispensable due to the limited availability of patient material.
Notably there is a desperate need for a speciﬁc antibody capable of
reliably detecting the PINK1 protein at the endogenous level inmitotic
and post-mitotic neuronal cell lines, which are better able to
recapitulate neurodegenerative disease.
In conclusion, there is increasing evidence that autophagy, and
mitophagy with respect to PD, are critically linked to the pathogenic
mechanisms underlying neurodegenerative disease. An importantquestion currently being raised, however, is whether autophagy or
mitophagy perform a protective role or whether their dysregulation is
in fact a common underlying cause of disease initiation. Given the
demonstration that activation of macroautophagy, in a mouse model
of HD, reduced both the presence of protein aggregates and neuronal
loss [79], suggests that modulation of the autophagy pathway in
mammals is possible and could be beneﬁcial in slowing down disease
pathogenesis. However, the potential to induce cell death via
excessive autophagic stimulation is a signiﬁcant risk and a much
greater understanding of how the process is regulated in multiple cell
types is crucial before beneﬁcial alterations can be induced via
therapeutics. With regards to mitophagy, it is clear that mitochondrial
dysfunction is directly linked to neurodegeneration and PD patho-
genesis in particular [102,103]. Neurons critically depend upon
mitochondrial respiration for energy and failure to eliminate
mitochondria, which have respiration defects and/or generate
increased levels of damaging ROS, will impose a signiﬁcant oxidative
burden over time. Our current understanding of the mitophagy
process, speciﬁcally which factors inﬂuence and signal its initiation
are still in their infancy. If, through further studies, we can unravel the
molecular mechanisms underlying both mitophagy and mitochondri-
al biogenesis, and develop methods to delicately modulate both
processes, it may be possible to enrich neuronal cells with the
healthiest mitochondrial population available (as demonstrated by
the recent in vitro study by Suen et al. [123]—Section 6.1). However,
driving mitophagy in a cell, which already has a severely damaged
mitochondrial population, without mitochondrial biogenesis, would
most likely eliminate a signiﬁcant number of the organelles and result
in neuronal death. Nevertheless, when we take into account the
speciﬁc regulation of mitophagy in different cell types, this opens up
an attractive avenue for therapeutic intervention where modulation
of the process could have the potential to target certain cell
populations without inducing detrimental effects on the remaining
organs and tissues of the brain/body.
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